Our regular readers probably know I have multiple myeloma and take an oral chemotherapy drug, Revlimid, each month. Now Celgene, the makers of Revlimid, are testing new drugs for patients with other blood cancers. Here is an example of one such study involving patients with peripheral T-cell lymphoma:
NEW CLINICAL DATA EVALUATING ISTODAX® IN PIVOTAL OPEN-LABEL PHASE II STUDY FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL)
Study reported primary endpoint reached, as 13% of patients achieved a complete response
Median duration of response was 12 months…
Celgene International today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.
This study showed patients with PTCL who failed or were refractory to prior systemic therapy had an overall response rate was 26%. Thirteen percent of patients achieved a complete response – the primary endpoint of the study – and another 13% achieved a partial response. The median duration of response for all patients who responded was 12 months. The median duration of response for patients who achieved a complete response has not been reached, and 82% of patients with a complete response had not progressed as of March 31, 2010.
Romidepsin (ISTODAX) is not yet approved for use in PTCL patients who have relapsed and become resistant to other therapies. Considering some of these patients are running out of options, these response rates look promising–especially if you are one of the 26% of patients who respond!
Feel good and keep smiling! Pat